celiprolol has been researched along with Cardiac Failure in 11 studies
Celiprolol: A cardioselective beta-1 adrenergic antagonist that has intrinsic sympathomimetic activity. It is used in the management of ANGINA PECTORIS and HYPERTENSION.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The present study was designed to investigate, in patients with severe heart failure, the dose-dependent acute hemodynamic effects of celiprolol versus those of esmolol." | 9.09 | Acute hemodynamic effects of beta-blockers in patients with severe congestive heart failure: comparison of celiprolol and esmolol. ( Baumann, G; Doerffel, W; Felix, SB; Kieback, A; Stangl, K; Stangl, V; Staudt, A; Wernecke, KD, 2001) |
| "This study examines the acute effects of two differing beta adrenergic blocking agents (metoprolol and a third generation vasodilating beta blocker) on plasma concentrations of atrial natriuretic factor (ANF), brain (ventricular) natriuretic factor (BNF), and haemodynamic variables in patients with heart failure." | 9.08 | Effect of low dose beta blockers on atrial and ventricular (B type) natriuretic factor in heart failure: a double blind, randomised comparison of metoprolol and a third generation vasodilating beta blocker. ( Chan, SK; Chan, WW; Hung, YT; Raymond, K; Sanderson, JE; Shum, IO; Woo, KS, 1995) |
| "To determine whether a third generation vasodilating beta blocker (celiprolol) has long term clinical advantages over metoprolol in patients with chronic heart failure." | 9.08 | Beta blockers in heart failure: a comparison of a vasodilating beta blocker with metoprolol. ( Chan, KW; Chan, SK; Chan, WM; Raymond, K; Sanderson, JE; Woo, KS; Yeung, LY; Yu, CM, 1998) |
| "Both celiprolol and candesartan showed cardioprotective effects in this heart failure model." | 7.73 | Mechanisms of combined treatment with celiprolol and candesartan for ventricular remodeling in experimental heart failure. ( Hayashi, T; Kitaura, Y; Matsumura, Y; Mori, T; Ohkita, M; Okuda, N; Shimomura, H; Sohmiya, K; Yoshikawa, J; Yoshiyama, M, 2005) |
| "These findings indicated that celiprolol attenuates cardiac myocyte hypertrophy both in vitro and in vivo and halts the process leading from hypertrophy to heart failure." | 7.72 | Celiprolol, a vasodilatory beta-blocker, inhibits pressure overload-induced cardiac hypertrophy and prevents the transition to heart failure via nitric oxide-dependent mechanisms in mice. ( Asakura, M; Asano, Y; Asanuma, H; Hori, M; Kim, J; Kitakaze, M; Kitamura, S; Liao, Y; Minamino, T; Ogai, A; Sanada, S; Shintani, Y; Takashima, S; Tomoike, H, 2004) |
| "To assess the effects of celiprolol, which is a selective beta1-antagonist with vasodilating properties, on chronic heart failure in the cardiomyopathic hamster UM-X7." | 7.70 | Celiprolol, a beta-adrenoceptor antagonist with vasodilator effect, improves hemodynamic response to catecholamine, spontaneous locomotor activity, and survival in cardiomyopathic hamsters with advanced heart failure. ( Matsuzaki, M; Nakamura, Y; Ohkusa, T; Ryoke, T; Tanaka, N, 1998) |
| "Impaired insulin sensitivity has been linked with chronic heart failure (CHF)." | 6.69 | Celiprolol augments the effect of physical exercise on insulin sensitivity and serum lipid levels in chronic heart failure. ( Huupponen, R; Malminiemi, K; Pere, E; Pietilä, M; Pulkki, K; Rouru, J; Voipio-Pulkki, LM, 2000) |
| "In this study, the effect of celiprolol (beta-1-antagonist with beta-2-agonistic activity) on hemodynamic and electrocardiographic parameters of patients with congestive heart failure due to ischemic (iCMP) and non-ischemic (niCMP) origin should be evaluated." | 5.09 | Hemodynamic effects of celiprolol in patients with ischemic and non-ischemic cardiomyopathy. ( Hennersdorf, MG; Perings, C; Vester, EG, 1999) |
| "The present study was designed to investigate, in patients with severe heart failure, the dose-dependent acute hemodynamic effects of celiprolol versus those of esmolol." | 5.09 | Acute hemodynamic effects of beta-blockers in patients with severe congestive heart failure: comparison of celiprolol and esmolol. ( Baumann, G; Doerffel, W; Felix, SB; Kieback, A; Stangl, K; Stangl, V; Staudt, A; Wernecke, KD, 2001) |
| "This study examines the acute effects of two differing beta adrenergic blocking agents (metoprolol and a third generation vasodilating beta blocker) on plasma concentrations of atrial natriuretic factor (ANF), brain (ventricular) natriuretic factor (BNF), and haemodynamic variables in patients with heart failure." | 5.08 | Effect of low dose beta blockers on atrial and ventricular (B type) natriuretic factor in heart failure: a double blind, randomised comparison of metoprolol and a third generation vasodilating beta blocker. ( Chan, SK; Chan, WW; Hung, YT; Raymond, K; Sanderson, JE; Shum, IO; Woo, KS, 1995) |
| "To determine whether a third generation vasodilating beta blocker (celiprolol) has long term clinical advantages over metoprolol in patients with chronic heart failure." | 5.08 | Beta blockers in heart failure: a comparison of a vasodilating beta blocker with metoprolol. ( Chan, KW; Chan, SK; Chan, WM; Raymond, K; Sanderson, JE; Woo, KS; Yeung, LY; Yu, CM, 1998) |
| "Both celiprolol and candesartan showed cardioprotective effects in this heart failure model." | 3.73 | Mechanisms of combined treatment with celiprolol and candesartan for ventricular remodeling in experimental heart failure. ( Hayashi, T; Kitaura, Y; Matsumura, Y; Mori, T; Ohkita, M; Okuda, N; Shimomura, H; Sohmiya, K; Yoshikawa, J; Yoshiyama, M, 2005) |
| "These findings indicated that celiprolol attenuates cardiac myocyte hypertrophy both in vitro and in vivo and halts the process leading from hypertrophy to heart failure." | 3.72 | Celiprolol, a vasodilatory beta-blocker, inhibits pressure overload-induced cardiac hypertrophy and prevents the transition to heart failure via nitric oxide-dependent mechanisms in mice. ( Asakura, M; Asano, Y; Asanuma, H; Hori, M; Kim, J; Kitakaze, M; Kitamura, S; Liao, Y; Minamino, T; Ogai, A; Sanada, S; Shintani, Y; Takashima, S; Tomoike, H, 2004) |
| "To assess the effects of celiprolol, which is a selective beta1-antagonist with vasodilating properties, on chronic heart failure in the cardiomyopathic hamster UM-X7." | 3.70 | Celiprolol, a beta-adrenoceptor antagonist with vasodilator effect, improves hemodynamic response to catecholamine, spontaneous locomotor activity, and survival in cardiomyopathic hamsters with advanced heart failure. ( Matsuzaki, M; Nakamura, Y; Ohkusa, T; Ryoke, T; Tanaka, N, 1998) |
| "Impaired insulin sensitivity has been linked with chronic heart failure (CHF)." | 2.69 | Celiprolol augments the effect of physical exercise on insulin sensitivity and serum lipid levels in chronic heart failure. ( Huupponen, R; Malminiemi, K; Pere, E; Pietilä, M; Pulkki, K; Rouru, J; Voipio-Pulkki, LM, 2000) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 6 (54.55) | 18.2507 |
| 2000's | 5 (45.45) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Liao, Y | 1 |
| Asakura, M | 1 |
| Takashima, S | 1 |
| Ogai, A | 1 |
| Asano, Y | 1 |
| Shintani, Y | 1 |
| Minamino, T | 1 |
| Asanuma, H | 1 |
| Sanada, S | 1 |
| Kim, J | 1 |
| Kitamura, S | 1 |
| Tomoike, H | 1 |
| Hori, M | 1 |
| Kitakaze, M | 1 |
| Mori, T | 1 |
| Hayashi, T | 1 |
| Sohmiya, K | 1 |
| Okuda, N | 1 |
| Shimomura, H | 1 |
| Ohkita, M | 1 |
| Matsumura, Y | 1 |
| Yoshiyama, M | 1 |
| Yoshikawa, J | 1 |
| Kitaura, Y | 1 |
| Sanderson, JE | 3 |
| Chan, WW | 1 |
| Hung, YT | 1 |
| Chan, SK | 2 |
| Shum, IO | 1 |
| Raymond, K | 2 |
| Woo, KS | 3 |
| Nakamura, Y | 1 |
| Ryoke, T | 1 |
| Tanaka, N | 1 |
| Ohkusa, T | 1 |
| Matsuzaki, M | 1 |
| Yu, CM | 1 |
| Yeung, LY | 2 |
| Chan, WM | 1 |
| Chan, KW | 1 |
| Chan, S | 1 |
| Tomlinson, B | 1 |
| Kay, R | 1 |
| Bernardi, L | 1 |
| Hennersdorf, MG | 1 |
| Perings, C | 1 |
| Vester, EG | 1 |
| Pietilä, M | 1 |
| Malminiemi, K | 1 |
| Huupponen, R | 1 |
| Rouru, J | 1 |
| Pulkki, K | 1 |
| Pere, E | 1 |
| Voipio-Pulkki, LM | 1 |
| Witchitz, S | 1 |
| Cohen-Solal, A | 1 |
| Dartois, N | 1 |
| Weisslinger, N | 1 |
| Juste, K | 1 |
| Darmon, JY | 1 |
| Felix, SB | 1 |
| Stangl, V | 1 |
| Kieback, A | 1 |
| Doerffel, W | 1 |
| Staudt, A | 1 |
| Wernecke, KD | 1 |
| Baumann, G | 1 |
| Stangl, K | 1 |
| Strein, K | 1 |
| Sponer, G | 1 |
1 review available for celiprolol and Cardiac Failure
| Article | Year |
|---|---|
Experimental and clinical pharmacology of carvedilol and other drugs combining vasodilation and beta-adrenoceptor antagonism in a single molecule.
Topics: Adrenergic beta-Antagonists; Animals; Carbazoles; Carvedilol; Celiprolol; Coronary Disease; Heart Fa | 1990 |
7 trials available for celiprolol and Cardiac Failure
| Article | Year |
|---|---|
Effect of low dose beta blockers on atrial and ventricular (B type) natriuretic factor in heart failure: a double blind, randomised comparison of metoprolol and a third generation vasodilating beta blocker.
Topics: Adrenergic beta-Antagonists; Atrial Natriuretic Factor; Celiprolol; Double-Blind Method; Female; Hea | 1995 |
Beta blockers in heart failure: a comparison of a vasodilating beta blocker with metoprolol.
Topics: Adrenergic beta-Antagonists; Aged; Analysis of Variance; Celiprolol; Chi-Square Distribution; Double | 1998 |
Effect of beta-blockade on baroreceptor and autonomic function in heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Analysis of Variance; Autonomic Nervous System; Blood Pressure; C | 1999 |
Hemodynamic effects of celiprolol in patients with ischemic and non-ischemic cardiomyopathy.
Topics: Adrenergic beta-Agonists; Adrenergic beta-Antagonists; Cardiac Catheterization; Cardiomyopathies; Ca | 1999 |
Celiprolol augments the effect of physical exercise on insulin sensitivity and serum lipid levels in chronic heart failure.
Topics: Adrenergic beta-Antagonists; Celiprolol; Cholesterol, HDL; Cholesterol, LDL; Exercise; Female; Heart | 2000 |
Treatment of heart failure with celiprolol, a cardioselective beta blocker with beta-2 agonist vasodilatory properties. The CELICARD Group.
Topics: Adrenergic beta-Antagonists; Adult; Celiprolol; Double-Blind Method; Female; Heart Failure; Humans; | 2000 |
Acute hemodynamic effects of beta-blockers in patients with severe congestive heart failure: comparison of celiprolol and esmolol.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Celiprolol; Dose-Response Relationship, Drug; Half-Life; H | 2001 |
3 other studies available for celiprolol and Cardiac Failure
| Article | Year |
|---|---|
Celiprolol, a vasodilatory beta-blocker, inhibits pressure overload-induced cardiac hypertrophy and prevents the transition to heart failure via nitric oxide-dependent mechanisms in mice.
Topics: Adrenergic beta-1 Receptor Antagonists; Adrenergic beta-Antagonists; Animals; Cardiomegaly; Celiprol | 2004 |
Mechanisms of combined treatment with celiprolol and candesartan for ventricular remodeling in experimental heart failure.
Topics: Animals; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Celiprolol; Disease Models, An | 2005 |
Celiprolol, a beta-adrenoceptor antagonist with vasodilator effect, improves hemodynamic response to catecholamine, spontaneous locomotor activity, and survival in cardiomyopathic hamsters with advanced heart failure.
Topics: Adrenergic beta-Agonists; Adrenergic beta-Antagonists; Analysis of Variance; Animals; Body Weight; C | 1998 |